临床医学工程
臨床醫學工程
림상의학공정
CLINICAL MEDICAL ENGINEERING
2014年
6期
739-740
,共2页
宋云峰%胡英芳%罗文娟%邢锐
宋雲峰%鬍英芳%囉文娟%邢銳
송운봉%호영방%라문연%형예
血必净%重症脓毒症%脓毒症休克%临床疗效
血必淨%重癥膿毒癥%膿毒癥休剋%臨床療效
혈필정%중증농독증%농독증휴극%림상료효
Xuebijing%Severe sepsis%Septic shock%Clinical curative effect
目的:探讨血必净治疗重症脓毒症和脓毒症休克的临床疗效。方法入选2010年1月至2013年12月我院收治的126例重症脓毒症和脓毒症休克患者,随机分为试验组和对照组。对照组60例采用常规治疗措施,试验组66例在对照组基础上加用血必净治疗。比较两组患者病死率的差异,并评价患者APACHEⅡ评分情况。结果试验组治疗后病死率为18.1%显著低于对照组38.3%,有统计学差异(P<0.05);治疗后试验组APACHE II评分显著下降,有统计学差异(P<0.05),且明显低于同期对照组,有统计学差异(P<0.05)。结论血必净治疗重症脓毒症和脓毒症休克疗效显著,能够显著降低患者临床病死率,促进患者恢复,提高其生活质量。同时,能明显降低患者APACHEⅡ评分,缓解病情严重度,提高患者健康生理状态,值得临床选择。
目的:探討血必淨治療重癥膿毒癥和膿毒癥休剋的臨床療效。方法入選2010年1月至2013年12月我院收治的126例重癥膿毒癥和膿毒癥休剋患者,隨機分為試驗組和對照組。對照組60例採用常規治療措施,試驗組66例在對照組基礎上加用血必淨治療。比較兩組患者病死率的差異,併評價患者APACHEⅡ評分情況。結果試驗組治療後病死率為18.1%顯著低于對照組38.3%,有統計學差異(P<0.05);治療後試驗組APACHE II評分顯著下降,有統計學差異(P<0.05),且明顯低于同期對照組,有統計學差異(P<0.05)。結論血必淨治療重癥膿毒癥和膿毒癥休剋療效顯著,能夠顯著降低患者臨床病死率,促進患者恢複,提高其生活質量。同時,能明顯降低患者APACHEⅡ評分,緩解病情嚴重度,提高患者健康生理狀態,值得臨床選擇。
목적:탐토혈필정치료중증농독증화농독증휴극적림상료효。방법입선2010년1월지2013년12월아원수치적126례중증농독증화농독증휴극환자,수궤분위시험조화대조조。대조조60례채용상규치료조시,시험조66례재대조조기출상가용혈필정치료。비교량조환자병사솔적차이,병평개환자APACHEⅡ평분정황。결과시험조치료후병사솔위18.1%현저저우대조조38.3%,유통계학차이(P<0.05);치료후시험조APACHE II평분현저하강,유통계학차이(P<0.05),차명현저우동기대조조,유통계학차이(P<0.05)。결론혈필정치료중증농독증화농독증휴극료효현저,능구현저강저환자림상병사솔,촉진환자회복,제고기생활질량。동시,능명현강저환자APACHEⅡ평분,완해병정엄중도,제고환자건강생리상태,치득림상선택。
Objective To investigate the clinical curative effect of Xuebijing in the treatment of severe sepsis and septic shock. Methods 126 patients with severe sepsis and septic shock treated in our hospital from January 2010 to December 2013 were selected and randomly divided into the experimental group and the control group. 60 patients in the control group received routine treatment, and 66 cases in the experimental group were treated with Xuebijing in additional to the routine therapy. The primary outcome was a composite of a comparison of the difference in mortality between the two groups, and an evaluation of patients' APACHE II score. Results The mortality rate of the experimental group after treatment was 18.1%, significantly lower than that of the control group (38.3%), with significant difference (P <0.05). And the APACHEIIscore of the experimental group after treatment decreased remarkably (P <0.05), significantly lower than that of the control group (P <0.05). Conclusions Applying Xuebijing in the treatment of severe sepsis and septic shock has profound effect, which can significantly reduce the mortality rate, enhance patients' recovery, improve the quality of life. Meanwhile, it can significantly reduce patients' APACHEIIscore, relieve patients' condition, improve patients' physiological state. It is worthy to be applied clinically.